Skip to main content

Michael D Deel, MD

Assistant Professor of Pediatrics
Member of the Duke Cancer Institute
Member of the Duke Cancer Institute
Campus mail: Duke University Medical Center, Box 102382, Durham, NC 27710
Phone: (919) 681-6173
Email address: michael.deel@duke.edu

Dr. Deel is a clinician scientist in Pediatric Hematology/Oncology. In addition to caring for pediatric patients with hematologic disorders or malignancy, his research focuses on finding novel ways to target fusion-positive pediatric sarcomas. His current work focuses on understanding the gene regulation and molecular pathways responsible for alveolar rhabdomyosarcoma, which is among the most difficult to cure pediatric cancers. Alveolar rhabdomyosarcoma is driven by chromosomal translocations t(2;13) or t(1;13) that result in oncogenic transcription factors encoding for PAX3/7-FOXO1 fusion proteins. The PAX3/7-FOXO1 oncogenes are currently not viable therapeutic targets. Using a variety of cell culture and murine models, Dr. Deel is investigating genes and pathways that regulate or coordinate PAX3/7-FOXO1-mediated tumorigenesis.

Education and Training

  • Advanced Pediatric/Oncology Research Training, Pediatrics/Duke University School Of Medicine, Duke University School of Medicine, 2016 - 2017
  • Pediatric Hematology/Oncology Fellowship, Pediatrics/Duke University School Of Medicine, Duke University School of Medicine, 2013 - 2016
  • Internshipand Residency, Pediatrics/University Of Louisville, University of Louisville, 2010 - 2013
  • M.D., Marshall University Joan C. Edwards School of Medicine, 2010

Publications

Deel, MD, Slemmons, KK, Hinson, AR, Genadry, KC, Burgess, BA, Crose, LES, Kuprasertkul, N, Oristian, KM, Bentley, RC, and Linardic, CM. "The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 24, no. 11 (June 2018): 2616-2630.

Full Text

Deel, MD, Li, JJ, Crose, LES, and Linardic, CM. "A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas." Frontiers in Oncology 5 (January 2015): 190-null. (Review)

Full Text

Deel, MD, Kong, M, Cross, KP, and Bertolone, SJ. "Absolute lymphocyte counts as prognostic indicators for immune thrombocytopenia outcomes in children." Pediatric blood & cancer 60, no. 12 (December 2013): 1967-1974.

Full Text